Drugging IGF-1R in cancer: New insights and emerging opportunities

Panpan Wang; Victor CY. Mak; Lydia WT. Cheung

doi:10.1016/j.gendis.2022.03.002

您当前的位置：

首页 >

文章列表页 >

Drugging IGF-1R in cancer: New insights and emerging opportunities

更新时间：2023-08-29

- Drugging IGF-1R in cancer: New insights and emerging opportunities
- Genes & Diseases Vol. 10, Issue 1, (2023)
- 作者机构：
  
  School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong,Hong Kong SAR,China
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2022.03.002
  CLC：
- Published：2023，
  
  Published Online：1 January 2023，
扫描看全文
Panpan Wang, Victor CY. Mak, Lydia WT. Cheung. Drugging IGF-1R in cancer: New insights and emerging opportunities. [J]. Genes & Diseases 10(1).(2023)
DOI：

Panpan Wang, Victor CY. Mak, Lydia WT. Cheung. Drugging IGF-1R in cancer: New insights and emerging opportunities. [J]. Genes & Diseases 10(1).(2023) DOI： 10.1016/j.gendis.2022.03.002.

摘要

Abstract

The insulin-like growth factor (IGF) axis plays important roles in cancer development and metastasis. The type 1 IGF receptor (IGF-1R) is a key member in the IGF axis and has long been recognized for its oncogenic role in multiple cancer lineages. Here we review the occurrence of IGF-1R aberrations and activation mechanisms in cancers

which justify the development of anti-IGF-1R therapies. We describe the therapeutic agents available for IGF-1R inhibition

with focuses on the recent or ongoing pre-clinical and clinical studies. These include antisense oligonucleotide

tyrosine kinase inhibitors and monoclonal antibodies which may be conjugated with cytotoxic drug. Remarkably

simultaneous targeting of IGF-1R and several other oncogenic vulnerabilities has shown early promise

highlighting the potential benefits of combination therapy. Further

we discuss the challenges in targeting IGF-1R so far and new concepts to improve therapeutic efficacy such as blockage of the nuclear translocation of IGF-1R.

关键词

Keywords

CancerIGF-1RTargeted therapyMetastasisCombination therapy

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

The evolving roles of Wnt signaling in stem cell proliferation and differentiation, the development of human diseases, and therapeutic opportunities

The emerging role of Arid5a in cancer: A new target for tumors

MicroRNA-9 as a paradoxical but critical regulator of cancer metastasis: Implications in personalized medicine

The Hippo Tumor Suppressor Pathway (YAP/TAZ/TEAD/MST/LATS) and EGFR-RAS-RAF-MEK in cancer metastasis

Colony-stimulating factor-1 receptor inhibition combined with paclitaxel exerts effective antitumor effects in the treatment of ovarian cancer

Related Author

Michael Yu

Kevin Qin

Jiaming Fan

Guozhi Zhao

Piao Zhao

Wei Zeng

Connie Chen

Annie Wang

Related Institution

Department of Urology, The First Affiliated Hospital of Chongqing Medical University

School of Medicine, Rosalind Franklin University of Medicine and Science, North Chicago

Department of Clinical Laboratory Medicine, Shanghai Jiaotong University School of Medicine

Laboratory of Craniofacial Suture Biology and Development, Department of Surgery Section of Plastic Surgery, The University of Chicago Medical Center

Department of Neurology, The First Dongguan Affiliated Hospital, Guangdong Medical University

⁰